ATE494905T1 - Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom - Google Patents

Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom

Info

Publication number
ATE494905T1
ATE494905T1 AT08013828T AT08013828T ATE494905T1 AT E494905 T1 ATE494905 T1 AT E494905T1 AT 08013828 T AT08013828 T AT 08013828T AT 08013828 T AT08013828 T AT 08013828T AT E494905 T1 ATE494905 T1 AT E494905T1
Authority
AT
Austria
Prior art keywords
product
cancer
suppressor gene
tumor suppressor
vaccine containing
Prior art date
Application number
AT08013828T
Other languages
English (en)
Inventor
Tadanori Mayumi
Haruo Sugiyama
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadanori Mayumi
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Tadanori Mayumi, Haruo Sugiyama filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE494905T1 publication Critical patent/ATE494905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08013828T 2001-06-29 2002-06-28 Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom ATE494905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001199449 2001-06-29

Publications (1)

Publication Number Publication Date
ATE494905T1 true ATE494905T1 (de) 2011-01-15

Family

ID=19036745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08013828T ATE494905T1 (de) 2001-06-29 2002-06-28 Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom

Country Status (9)

Country Link
US (2) US20060165708A1 (de)
EP (2) EP2014300B1 (de)
JP (2) JP4229832B2 (de)
CN (1) CN1320923C (de)
AT (1) ATE494905T1 (de)
CA (1) CA2451846A1 (de)
DE (1) DE60238958D1 (de)
HK (1) HK1064589A1 (de)
WO (1) WO2003002142A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443582T3 (es) * 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
US20070212403A1 (en) * 2003-11-03 2007-09-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for Selecting Cationic or Anionic Liposomes for Treatment of a Mucosa Membrane, and Kit Comprising the Same
CA2544214C (en) * 2003-11-05 2018-08-28 International Institute Of Cancer Immunology, Inc. Hla-dr-binding antigen peptide derived from wt1
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
EP1657250A1 (de) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A*01 bindendes T-Zell-Epitop von WT1
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
JP5002749B2 (ja) * 2006-03-22 2012-08-15 富士フイルム株式会社 癌抑制剤
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
JP2008031063A (ja) * 2006-07-27 2008-02-14 Fujifilm Corp 癌抑制剤
KR101598228B1 (ko) 2007-02-27 2016-02-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법 및 그를 위한 조성물
JPWO2008105174A1 (ja) * 2007-02-28 2010-06-03 国立大学法人北海道大学 細胞性免疫誘導用リポソーム
JP5808079B2 (ja) 2007-03-05 2015-11-10 株式会社癌免疫研究所 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
CN110075113A (zh) 2008-04-17 2019-08-02 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
MY170306A (en) 2010-10-05 2019-07-17 Int Inst Cancer Immunology Inc Method for activating helper t cell
WO2012105224A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 ワクチン・アジュバント
JP6066909B2 (ja) 2011-06-28 2017-01-25 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US8562681B2 (en) 2012-01-31 2013-10-22 Styker Spine Laminoplasty implant, method and instrumentation
JP2015530413A (ja) 2012-09-21 2015-10-15 ベデュ−アッド，フランク 改良されたワクチン組成物および使用方法
ES2805337T3 (es) 2012-12-17 2021-02-11 Otsuka Pharma Co Ltd Método para activar células T auxiliares
JP6486278B2 (ja) 2013-01-15 2019-03-20 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ−１ペプチドおよびその使用法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
DE102015201207B4 (de) 2014-06-24 2019-02-21 Sms Group Gmbh Viersattelpressenwerkzeug und Schmiedepresse sowie Verfahren zum Schmieden eines Werkstücks
EP4092112A1 (de) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
WO2023212095A1 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Molecules that enhance extracellular vesicle release

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US104627A (en) 1870-06-21 Improvement in churn-power
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
JP4243792B2 (ja) * 1998-09-30 2009-03-25 コリクサ コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Also Published As

Publication number Publication date
EP1410804A1 (de) 2004-04-21
JP2009079054A (ja) 2009-04-16
CA2451846A1 (en) 2003-01-09
CN1520311A (zh) 2004-08-11
US20060165708A1 (en) 2006-07-27
EP1410804A4 (de) 2007-10-24
DE60238958D1 (de) 2011-02-24
JPWO2003002142A1 (ja) 2004-10-14
EP2014300B1 (de) 2011-01-12
CN1320923C (zh) 2007-06-13
US20090098197A1 (en) 2009-04-16
WO2003002142A8 (en) 2003-12-11
EP2014300A1 (de) 2009-01-14
HK1064589A1 (en) 2005-02-04
WO2003002142A1 (en) 2003-01-09
JP4229832B2 (ja) 2009-02-25

Similar Documents

Publication Publication Date Title
ATE494905T1 (de) Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
RU94045155A (ru) Способы ингибирования болезни альцгеймера
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
NO20015073D0 (no) Vaksiner
ATE374609T1 (de) Synthese von 4-aminothalidomid enantiomeren
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
HK1068606A1 (en) Novel aminobenzoephenones
ATE297750T1 (de) Verwendung von hsp70 protein
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
MX2020009150A (es) Anfifilos de cpg y usos de los mismos.
DE69841858D1 (de) Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten
DK0655926T3 (da) Ny sonde til tumordiagnose eller tumorterapi
FR2746110B1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
DE69514217D1 (de) Rekombinante plasmide enthaltende zusammensetzung und ihre verwendung als impstoff und arzneimittel
JP2005507888A5 (de)
ES2192608T3 (es) Uso de derivados de alilamina tales como terbinafina, en la fabricacion de un medicamento para el tratamiento de la infeccion por helicobacter pylori de enfermedades asociadas.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE60222662D1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties